ImpediMed Limited

Suite 31C, 12-18 Tryon Rd
Lindfield NSW 2070
Australia

E: investorrelations@impedimed.com
W: impedimed.com

13 August 2026

Companies Announcements Office
Australian Securities Exchange

ASX Listing Rule 7.16 Compliance

ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company)** advises the market of a breach of ASX Listing Rule 7.16 and a related breach of ASX Listing Rule 3.10.3E, the circumstances that gave rise to the breach, and the steps the Company has taken and is taking to restore and maintain compliance with the ASX Listing Rules.

ASX Listing Rule 7.16 requires that the number of convertible securities on issue must not exceed the number of ordinary securities on issue.

Following a review of the Company's capital structure, the Company determined that upon the issue of options on 16 June 2026 in connection with the Company's recent capital raising, the number of convertible securities on issue exceeded the number of ordinary shares on issue, resulting in a breach of ASX Listing Rule 7.16.

On 16 June 2026, the number of convertible securities on issue exceeded the number of ordinary shares on issue by approximately 25,842,829 securities.

From 30 June 2026, following the lapse of 20,172,661 convertible securities (which was announced on 3 July 2026), the number of convertible securities on issue exceeded the number of ordinary shares on issue by approximately 2,981,830 securities.

The Company subsequently determined a further 2,635,000 employee options had lapsed on 30 June 2026. The cessation of those options was notified to ASX on 20 July 2026, when the Company lodged an Appendix 3H. As a result, while the extent of the ASX Listing Rule 7.16 breach reduced to approximately 346,830 convertible securities from 30 June 2026, the Company remained in breach of ASX Listing Rule 7.16. The delayed lodgement of the Appendix 3H also constituted a separate breach of ASX Listing Rule 3.10.3E, which requires notification within 10 business days following the end of the quarter in which the cessation occurred.

On 30 July 2026, a further 2,125,000 employee options held by a former employee lapsed in accordance with their terms. From the lapsing of those options, the number of convertible securities on issue does not exceed the number of ordinary shares on issue and the Company returned to compliance with ASX Listing Rule 7.16. The Company has lodged the relevant Appendix 3H in respect of that cessation.

The Company takes compliance with the ASX Listing Rules seriously and has undertaken a review of the circumstances that gave rise to these breaches. The review found the breach arose from a miscalculation of the number of convertible securities on issue for the purposes of ASX Listing Rule 7.16, including by taking into account anticipated employee option lapses that had not yet occurred.

As a result of that review, the Company has implemented and will maintain additional measures to support ongoing ASX Listing Rule compliance. This includes adding a step on its compliance checklist requiring verification of ASX Listing Rule 7.16 capacity before any future issue of options or other convertible securities and enhancing its compliance calendar to monitor and ensure timely lodgement of all required ASX notifications, including Appendix 3H notices.

This announcement has been authorised for release by the Board of Directors.